Pharmacological Approaches of Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 March 2025 | Viewed by 59
Special Issue Editors
Interests: epigenetics related to thyroid and lung carcinogenesis; autoimmune diseases; chronic stress; molecular biology; miRNA and cfDNA circulating biomarkers; liquid biopsy; microbiota analysis
Special Issues, Collections and Topics in MDPI journals
Interests: respiratory dynamics; inhalation toxicology; aerosol-based tumor diagnosis; personalized drug delivery; snoring and apnea; medical devices; machine learning
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. It is characterized by limited lung airflow and tissue damage, often from chronic bronchitis involving airway inflammation and scarring. The progression of inflammation and ioxidant–antioxidant imbalances triggers emphysema formation. The presence of COPD is a significant risk factor for lung cancer (LC) development independent of smoking behavior. The pathogenesis of both COPD and LC includes chronic inflammation, and lately, inflammasomes are gaining more and more interest.
Current treatments for COPD include inhaled corticosteroids and bronchodilator therapy, but they do not effectively stop disease progression. Due to the intricate nature of its pathophysiology and the potential to worsen symptoms with current therapies, there is a necessity for more precise and effective treatment options.
Therapies directly or indirectly target prolonged chronic inflammation and inflammasome activation, which is an important process present in COPD and LC and can alter the disease treatment.
It is important to note that inflammasome activation is considered a therapeutic target for cancer prevention and treatment. Additionally, there have been randomized clinical trials targeting inflammasome-related effectors (such as IL-1α and IL-1β) in treating COPD.
Therefore, understanding the molecular mechanisms behind chronic obstructive pulmonary disease and lung cancer development may improve the current pharmacotherapy as well as indicate new therapeuthic targets and procedures. It would also have a great impact on clinical practice by improving our current therapeutic options or by helping the development of new treatment targets. The goal of this Special Issue is to highlight the new scientific achievements related to COPD and LC etiopathogenesis in realtion to the therapeutic approaches.
Dr. Karolina H. Czarnecka-Chrebelska
Dr. Jinxiang Xi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic obstructive pulmonary disease (COPD)
- inflammasomes
- lung cancer (LC)
- chronic bronchitis
- cancer prevention and treatment
- therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
